RNS Number : 6181N
N4 Pharma PLC
01 October 2021

1 October 2021

N4 Pharma Plc

("N4 Pharma" or the "Company")

EPO Patent Granted

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that further to the Company's announcement dated 11 February 2021 in which it was stated that the European Patent Office ("EPO") had notified the Company of its intention to grant a European patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"), the EPO has now granted this Patent which has been validated in the main territories across Europe*. This Patent adds to existing grants in Australia and Japan.

The Company is also pleased to announce that it has been informed by the Chinese Patent Office ("CPO") of its intention to grant the Patent in China in relation to Nuvec®.

Discussions with other key patent authorities in the US, Canada and India are continuing and updates will be provided by the Company on these in due course.

Nigel Theobald, Chief Executive Officer of the Company, commented: "We are delighted that the EPO has now formally granted the European Patent which is now validated across Europe. This achieves another key step in our IP strategy where we are also making excellent progress following the notice of allowance made recently by the CPO for the potentially huge market of China and the ongoing discussions in other key jurisdictions. We look forward to updating the market on these in due course."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

*European territories validated are: United Kingdom, France, Germany, Spain, Italy, Netherlands, Switzerland, Sweden, Denmark, Ireland, Malta, Belgium, Portugal, Norway, Poland

Enquiries:

N4 Pharma Plc **Via IFC Advisory**

Nigel Theobald, CEO

Luke Cairns, Executive Director

SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited **Tel: +44 (0)20 3657 0050**

Joint Broker

Andy Thacker

IFC Advisory Limited **Tel: +44 (0)20 3934 6630**

Financial PR

Graham Herring

Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as

part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FURURUVRAKUKOAR